Danco Laboratories, the sole manufacturer of the branded abortion pill Mifeprex, filed an emergency request with the Supreme Court on Saturday asking the justices to block a Fifth Circuit ruling that immediately reinstated a nationwide in-person dispensing requirement for mifepristone. The filing came less than twenty-four hours after the appeals court granted Louisiana's request to roll back years of loosened FDA access rules, a move Danco called "unprecedented."
The speed of the legal volley is remarkable even by the standards of the post-Roe abortion fight. On Friday night, the Fifth Circuit U.S. Court of Appeals sided with Louisiana and reinstated the old requirement that mifepristone be dispensed only in person, effectively banning distribution by telehealth or mail nationwide. By Saturday, NBC News reported that Danco's lawyers had already asked the high court for an immediate stay.
The case sits at the intersection of federal drug regulation, state sovereignty, and the ongoing legal battle over medication abortion that has intensified since the Supreme Court overturned Roe v. Wade in 2022.
The FDA in 2023 permanently installed a Covid-era rule allowing mifepristone to be prescribed via telehealth and shipped by mail. That policy had been in effect for over five years by the time the Fifth Circuit acted, Danco's filing noted. Louisiana challenged the FDA's guidance last year, arguing the agency overstepped its authority.
The Fifth Circuit agreed. Its Friday-night order immediately restored the pre-2023 requirement that abortion pills be dispensed in person, not just in Louisiana, but across the entire country.
That breadth is what Danco's lawyers seized on in their Supreme Court filing. They argued that a single state's legal challenge should not be allowed to upend drug-distribution rules for the whole nation overnight.
"At a minimum, the stay factors show that the public interest and equities weigh against allowing the Fifth Circuit to change the availability of a drug nationwide at the request of a single state."
The filing also described the ruling as a break from normal procedure. Rather than blocking a new agency action before it took effect, Danco argued, the Fifth Circuit retroactively stripped away conditions that had governed mifepristone distribution for years.
"Far from seeking an ordinary stay of a new agency action that has not yet gone into effect, the court immediately, upon the issuance of its order, stayed conditions on the distribution of mifepristone that have been in effect for over five years. This is unprecedented."
Danco's filing leaned heavily on the financial consequences. Mifeprex is the company's only product. Without the current distribution framework, Danco told the Court, it would "lose its only source of revenue and may be unable to continue operating." The company called that harm "irreparable."
That framing deserves scrutiny. A company built entirely around a single controversial drug is, by definition, exposed to regulatory and legal risk. The argument that courts must preserve a company's revenue stream, even when a lower court has found the underlying FDA action likely unlawful, puts commercial interest ahead of the legal merits. Whether the justices buy it will say a great deal about how they weigh institutional disruption against regulatory accountability.
The Washington Free Beacon has reported on earlier rounds of this fight, noting that Justice Samuel Alito previously extended a temporary pause on lower-court mifepristone restrictions by two days to give the justices more time to weigh the dispute. In that earlier episode, the Biden administration and Danco warned the pill could become unavailable for months if restrictions took effect, an argument the Court took seriously enough to grant temporary relief.
The broader legal backdrop matters. The Fifth Circuit had previously found that the FDA's 2016 and 2021 changes expanding mifepristone access were likely unlawful. Those changes included allowing later use in pregnancy, mail distribution, and prescribing by non-doctors. As Breitbart reported, Judge Jennifer Walker Elrod wrote for the Fifth Circuit that "In loosening mifepristone's safety restrictions, FDA failed to address several important concerns about whether the drug would be safe for the women who use it."
That is not a minor procedural quibble. It goes to the heart of whether the FDA followed the law when it made mifepristone easier to obtain, or whether the agency bent its own rules under political pressure.
More than half of all abortions in the United States are now medication abortions. The telehealth-and-mail pipeline built under the FDA's 2023 policy made that possible on a scale that did not exist before. If the Fifth Circuit's ruling stands, the practical effect is a return to in-person dispensing, a requirement that abortion-rights groups say would sharply reduce access.
Planned Parenthood Action Fund President and CEO Alexis McGill Johnson framed the ruling in stark terms.
"In yesterday's Fifth Circuit ruling, activist judges once again upended countless lives by making it harder for patients to get the care they need, when and where they need it."
Johnson added that "Planned Parenthood will continue to make clear that mifepristone should be accessible, because it's safe and effective, full stop." The "activist judges" label is, of course, a familiar refrain from the left whenever a court reaches a conclusion progressives dislike. The Fifth Circuit did not invent a new rule. It restored an old one, one that existed before the FDA decided, during a pandemic, to let abortion pills travel through the mail.
The Supreme Court has found itself at the center of an increasing number of high-profile disputes that test the boundaries of federal agency power and state prerogatives. This case is another front in that broader conflict.
Louisiana's challenge rests on a straightforward claim: the FDA loosened safety restrictions on a powerful drug without adequate justification. The Fifth Circuit agreed, at least preliminarily. That finding should not be dismissed simply because the drug in question is politically sensitive.
Federal agencies do not get to rewrite their own rules and then claim that any court reversal is "unprecedented." The FDA made a policy choice. A state challenged it. A federal appeals court found the challenge had merit. That is the system working, not breaking down.
Louisiana has been active on multiple legal fronts recently. The state's willingness to press its case in federal court reflects a broader trend among conservative-led states pushing back against federal overreach through the judiciary.
Danco's filing asks the Supreme Court to freeze the Fifth Circuit's order while the justices decide whether to hear the full appeal. If the Court grants the stay, mifepristone distribution continues under the current telehealth-and-mail rules. If it declines, the in-person requirement takes effect nationwide.
The justices have not yet acted on the request as of the time Danco filed. How quickly they move, and whether they grant relief, will signal how seriously they take the disruption argument versus the underlying legal questions about FDA authority.
Strip away the rhetoric, and this dispute comes down to a simple question: can a federal agency permanently relax safety requirements for a drug used in more than half of all abortions, and then insist no court can undo that decision without causing irreparable harm?
Danco says yes. Louisiana says no. The Fifth Circuit sided with Louisiana. Now the Supreme Court will decide, again, how much deference the FDA deserves when it acts at the outer edge of its authority on one of the most politically charged issues in American life.
The Court's docket has grown crowded with cases testing the limits of federal power, from redistricting and voting rights to agency rulemaking and state sovereignty. Each case carries its own facts, but the pattern is unmistakable: states are no longer willing to accept Washington's word that its agencies acted lawfully, and courts are increasingly willing to look under the hood.
For pro-life Americans and anyone who believes federal agencies should follow the law rather than rewrite it for political convenience, the Fifth Circuit's ruling is not an outrage. It is accountability. The real question is whether the Supreme Court will let it stand long enough to matter, or whether the familiar pattern of emergency stays will once again preserve the status quo while the legal merits gather dust.
When a company's entire business model depends on a single regulatory favor, the courts are not the ones creating instability. The agency that handed out the favor is.
